Connection

LAWRENCE DONEHOWER to Genes, p53

This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Genes, p53.
Connection Strength

4.416
  1. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One. 2009 Aug 14; 4(8):e6654.
    View in: PubMed
    Score: 0.313
  2. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res. 2005 Aug 25; 576(1-2):4-21.
    View in: PubMed
    Score: 0.238
  3. p53: guardian AND suppressor of longevity? Exp Gerontol. 2005 Jan-Feb; 40(1-2):7-9.
    View in: PubMed
    Score: 0.227
  4. Insights into aging obtained from p53 mutant mouse models. Ann N Y Acad Sci. 2004 Jun; 1019:171-7.
    View in: PubMed
    Score: 0.218
  5. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002 Jan 03; 415(6867):45-53.
    View in: PubMed
    Score: 0.185
  6. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol. 2001; 29 Suppl:147-54.
    View in: PubMed
    Score: 0.172
  7. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol. 2001; 29 Suppl:24-9.
    View in: PubMed
    Score: 0.172
  8. Effect of intragastric application of N-methylnitrosourea in p53 knockout mice. Mol Carcinog. 2000 Jun; 28(2):97-101.
    View in: PubMed
    Score: 0.165
  9. Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53. Mol Carcinog. 1999 Mar; 24(3):197-208.
    View in: PubMed
    Score: 0.152
  10. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998 Aug 17; 17(16):4657-67.
    View in: PubMed
    Score: 0.146
  11. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ. 1997 Aug; 8(8):829-38.
    View in: PubMed
    Score: 0.136
  12. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol. 1996 Oct; 7(5):269-78.
    View in: PubMed
    Score: 0.128
  13. Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Biochim Biophys Acta. 1996 Mar 18; 1242(3):171-6.
    View in: PubMed
    Score: 0.124
  14. The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res. 1996; 395:1-11.
    View in: PubMed
    Score: 0.122
  15. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995 Sep; 14(1):16-22.
    View in: PubMed
    Score: 0.119
  16. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet. 1995 Mar; 9(3):305-11.
    View in: PubMed
    Score: 0.115
  17. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 1995 Mar 01; 55(5):1146-51.
    View in: PubMed
    Score: 0.115
  18. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993 Nov; 5(3):225-9.
    View in: PubMed
    Score: 0.105
  19. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene. 1993 Sep; 8(9):2457-67.
    View in: PubMed
    Score: 0.104
  20. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 1993 Jul; 7(10):938-43.
    View in: PubMed
    Score: 0.102
  21. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19; 356(6366):215-21.
    View in: PubMed
    Score: 0.094
  22. Altered mammary gland development in the p53+/m mouse, a model of accelerated aging. Dev Biol. 2008 Jan 01; 313(1):130-41.
    View in: PubMed
    Score: 0.069
  23. Early development of histiocytic sarcomas in p53 knockout mice treated with N-bis(2-hydroxypropyl)nitrosamine. Oncol Rep. 2007 Oct; 18(4):755-61.
    View in: PubMed
    Score: 0.069
  24. Organ-dependent susceptibility of p53 knockout mice to 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). Cancer Sci. 2007 Aug; 98(8):1164-73.
    View in: PubMed
    Score: 0.067
  25. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle. 2005 Aug; 4(8):1060-4.
    View in: PubMed
    Score: 0.059
  26. High susceptibility of nullizygous p53 knockout mice to colorectal tumor induction by 1,2-dimethylhydrazine. J Cancer Res Clin Oncol. 2003 Jun; 129(6):335-40.
    View in: PubMed
    Score: 0.051
  27. Generation and characterization of p53 mutant mice. Methods Mol Biol. 2003; 234:29-49.
    View in: PubMed
    Score: 0.049
  28. Visual genotyping of a coat color tagged p53 mutant mouse line. Cancer Biol Ther. 2002 Jul-Aug; 1(4):433-5.
    View in: PubMed
    Score: 0.048
  29. p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis. 2000 Oct; 21(10):1891-7.
    View in: PubMed
    Score: 0.042
  30. Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. Mol Carcinog. 2000 Oct; 29(2):67-75.
    View in: PubMed
    Score: 0.042
  31. Reduction in p53 gene dosage diminishes differentiation capacity of osteoblasts. Anticancer Res. 2000 Jul-Aug; 20(4):2553-9.
    View in: PubMed
    Score: 0.042
  32. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination. Cancer Res. 2000 Jun 01; 60(11):2831-5.
    View in: PubMed
    Score: 0.041
  33. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15608-12.
    View in: PubMed
    Score: 0.037
  34. Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice. Cell Growth Differ. 1997 Feb; 8(2):121-31.
    View in: PubMed
    Score: 0.033
  35. Genetic instability in animal tumorigenesis models. Cancer Surv. 1997; 29:329-52.
    View in: PubMed
    Score: 0.033
  36. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 1996 Oct 01; 56(19):4413-23.
    View in: PubMed
    Score: 0.032
  37. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J Neurosci. 1996 Feb 15; 16(4):1337-45.
    View in: PubMed
    Score: 0.031
  38. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene. 1995 Jul 06; 11(1):181-90.
    View in: PubMed
    Score: 0.029
  39. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene. 1995 May 04; 10(9):1717-23.
    View in: PubMed
    Score: 0.029
  40. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res. 1995 Apr 15; 55(8):1763-73.
    View in: PubMed
    Score: 0.029
  41. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene. 1995 Apr 06; 10(7):1269-74.
    View in: PubMed
    Score: 0.029
  42. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene. 1995 Mar 02; 10(5):869-79.
    View in: PubMed
    Score: 0.029
  43. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene. 1994 Dec; 9(12):3731-6.
    View in: PubMed
    Score: 0.028
  44. Gene-targeting and the p53 tumor-suppressor gene. Mutat Res. 1994 Jun 01; 307(2):557-72.
    View in: PubMed
    Score: 0.027
  45. Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol Carcinog. 1994 Mar; 9(3):175-83.
    View in: PubMed
    Score: 0.027
  46. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):9075-9.
    View in: PubMed
    Score: 0.026
  47. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell. 1993 Sep 10; 74(5):813-22.
    View in: PubMed
    Score: 0.026
  48. The tumor suppressor p53. Biochim Biophys Acta. 1993 Aug 23; 1155(2):181-205.
    View in: PubMed
    Score: 0.026
  49. REG? deficiency promotes premature aging via the casein kinase 1 pathway. Proc Natl Acad Sci U S A. 2013 Jul 02; 110(27):11005-10.
    View in: PubMed
    Score: 0.026
  50. DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle. 2006 Sep; 5(17):2005-11.
    View in: PubMed
    Score: 0.016
  51. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem. 2006 Mar 17; 281(11):7089-101.
    View in: PubMed
    Score: 0.015
  52. Organ-specific susceptibility of p53 knockout mice to N-bis(2-hydroxypropyl)nitrosamine carcinogenesis. Cancer Lett. 2006 Jul 18; 238(2):271-83.
    View in: PubMed
    Score: 0.015
  53. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A. 2000 Mar 28; 97(7):3461-6.
    View in: PubMed
    Score: 0.010
  54. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene. 2000 Mar 23; 19(13):1635-46.
    View in: PubMed
    Score: 0.010
  55. Transgenic mouse models for tumour-suppressor genes. J Intern Med. 1995 Sep; 238(3):233-8.
    View in: PubMed
    Score: 0.007
  56. Transgenic animals in toxicology. Fundam Appl Toxicol. 1994 Jan; 22(1):8-19.
    View in: PubMed
    Score: 0.007
  57. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol. 1994; 18(3):207-16.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.